Czechia· CZ-0225960
LIPANTHYL NT
A fenofibrate product, registered in Czechia by Mylan IRE Healthcare Limited, Dublin. The same ATC class is registered in 15 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Fenofibrate is registered in 15 of 19 countries.
Countries holding a registration under ATC C10AB05 (fenofibrate), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 10 of them publish a price we can compare per daily dose
Fenofibrate · ATC C10AB05
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Finlandprice
- Franceprice
- Germany
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of fenofibrate costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.22 in Spain to $1.30 in United States — a ×5.8 gap.
- 5 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Fenofibrate · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- US United States$1.30 (acquisition cost)
- CH Switzerland$0.75
- IT Italy$0.35
- FR France$0.24
- ES Spain$0.22
The record
At a glance
SÚKL (Czech Republic)- Manufacturer
- Mylan IRE Healthcare Limited, Dublin
- Country
- Czechia (CZ)
- ATC code
- C10AB05
- ATC class
- Fenofibrate
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- August 24, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
268 interactions on record for fenofibrate.
Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fenofibrate · interactions on record
268 records
- 10 severe
- 75 moderate
- 183 info
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- SimvastatinC10AA01severe
- RosuvastatinC10AA07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under C10AB05
Fenofibrate, as other registers publish it.
- CanadaAA-FENO-MICROAA PHARMA INC
- CanadaAA-FENO-MICROAA PHARMA INC
- CanadaAA-FENO-SUPERAA PHARMA INC
- CanadaAA-FENO-SUPERAA PHARMA INC
- United StatesAntaraLupin Pharmaceuticals, Inc.
- United StatesAntaraLupin Pharmaceuticals, Inc.
- United StatesANTARALupin Pharmaceuticals, Inc.
- United StatesANTARALupin Pharmaceuticals, Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f3f84fb9-feba-4bd4-8612-80cc8a7ec49b GET /v1/drugs/f3f84fb9-feba-4bd4-8612-80cc8a7ec49b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL FLM",
"source": "sukl",
"strength": "145MG",
"pack_size": "98",
"substance": "4352",
"cz_kod_sukl": "0225960",
"product_type": "CH",
"registration_state": "B",
"registration_number": "31/214/05-C"
}See everything about fenofibrate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.